Close Menu

NEW YORK (GenomeWeb News) - Illumina today said that it signed a definitive agreement to acquire Verinata Health for $350 million with additional potential milestone payments of up to $100 million through 2015.

The deal provides Illumina with Verinata’s Verifi non-invasive prenatal test for detecting trisomy 21, 18, and 13. The test analyzes cell-free fetal DNA using next-generation sequencing.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Russia says its candidate SARS-CoV-2 vaccine has a very high efficacy rate in an initial analysis of clinical trial data, according to the Financial Times.

Wired reports on a microbial analysis of sketches drawn by Leonardo DaVinci.

A new survey explores coronavirus vaccine hesitancy among Black and Latino individuals, the Washington Post reports.

In Nucleic Acids Research this week: the Aging Atlas database, a database of human metagenome-related metadata, and more.

Dec
01
Sponsored by
Roche

Management of viral infections is critical to prevent severe morbidities and consequences in immune-suppressed transplant patients.

Dec
02
Sponsored by
Qiagen

The Phosphoinositide 3-Kinase (PI3K) pathway is one of the most frequently altered pathways in human cancer and plays a significant role in disease progression and resistance to endocrine therapy.

Dec
15
Sponsored by
UgenTec

Diverse components of the UC Davis campus have been mobilized to deploy HTP testing to provide a safe working environment and keep the pandemic under control.